Osimertinib for EGFR-Mutated Advanced NSCLC: An Interview with Suresh S. Ramalingam, MD

The treatment of advanced-stage non-small cell lung cancer (NSCLC) has improved steadily in the past few years, and individualized therapy for patients with mutations in the epidermal growth factor receptor (EGFR) is applied in routine clinical practice. While EGFR-mutated NSCLC is effectively treated with tyrosine kinase inhibitors (TKIs) such as erlotinib or gefitinib, there is a need to develop more effective treatments to improve outcomes in these patients. In a study now published in The Ne...
Continue reading

Prescribing a Healthy Diet and Exercise for Breast Cancer With Neil Iyengar, MD

Patients with breast cancer can derive significant benefits from eating well and staying physically active during their treatment. In his previous interview with i3 Health, Neil Iyengar, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, explained the roles that nutrition and exercise can play in the prevention and treatment of breast cancer. In this second installment, Dr. Iyengar discusses the personalized strategies that are most likely to benefit patients. In addition, he of...
Continue reading

Nutrition and Exercise Before, During, and After Breast Cancer With Neil Iyengar, MD

Proper nutrition and adequate exercise can be considerably effective not only in helping to relieve symptoms and enhance quality of life in patients who have been diagnosed with breast cancer, but also to possibly prevent the development and progression of breast and other cancers. Neil Iyengar, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, has performed extensive research regarding the link between metabolic health and the development and recurrence of breast cancer, a top...
Continue reading

Atezolizumab/Bevacizumab for Advanced Renal Cell Carcinoma: Bradley McGregor, MD, and Toni Choueiri, MD

While metastatic renal cell carcinoma (RCC) has a five-year survival rate of only 10%, patients whose tumors have variant histology or sarcomatoid differentiation face an even more dismal outlook, with limited treatment options. In a study now published in the Journal of Clinical Oncology, a team of researchers led by Bradley McGregor, MD, and Toni Choueiri, MD, reported that atezolizumab in combination with bevacizumab significantly increased progression-free survival and improved outcomes in p...
Continue reading

Treatment Challenges and Advances in Hodgkin Lymphoma: Craig Moskowitz, MD, and Kami Maddocks, MD

In this exclusive with i3 Health, Craig H. Moskowitz, MD, Professor of Medicine at the University of Miami and Physician-in-Chief at the Sylvester Comprehensive Cancer Center, and Kami Maddocks, MD, Associate Professor of Clinical Internal Medicine and Lymphoma Program Director at The James Cancer Hospital at The Ohio State University, share their perspectives on the management of relapsed/refractory classical Hodgkin lymphoma (HL) and the advances brought to the treatment of this disease by dev...
Continue reading

© Copyright 2019 i3 Health. All rights reserved.